Pilot (OTC:POGHF) Stock, Quote.Headers.trade-ideas

Pilot Corp is a Japanese company that manufactures, purchases, and distributes stationery items including writing instruments, other stationery products and toys, and relevant services. The company operates through four segments: Japan, the Americas, Europe, and Asia. The Japan segment distributes products through direct sales to retail stores in Japan, and this segment contributes the largest proportion of total group revenue. The Americas segment is mainly engaged in the manufacture and sales of ball pens in the United States, Mexico and Brazil. The Europe segment operates in Sweden, the United Kingdom, Germany, France, and others. The Asia segment provides writing materials in Taiwan, mainland China, Hong Kong, Indonesia, Malaysia, and Singapore.

Pilot Corp

<p>Cantor Fitzgerald  analyst Kristen Kluska   reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Overweight and maintains $21 price target.</p>


News

Price Target

Reiteration

Analyst Ratings

FOLD

Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $21 Price Target

<p>Evercore ISI Group  analyst James West   downgrades Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) from Outperform to In-Line and lowers the price target from $6 to $5.</p>


Downgrades

Evercore ISI Group Downgrades Transocean to In-Line, Lowers Price Target to $5

<p>Cantor Fitzgerald  analyst Kristen Kluska   maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $80 to $76.</p>


PTCT

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $76

<p>Canaccord Genuity  analyst Austin Moeller   maintains Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) with a Buy and maintains $6 price target.</p>


BAER

Canaccord Genuity Maintains Buy on Bridger Aerospace Gr, Maintains $6 Price Target

<p>Cantor Fitzgerald  analyst Brett Knoblauch   maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Overweight and lowers the price target from $15 to $14.</p>


APLD

Cantor Fitzgerald Maintains Overweight on Applied Digital, Lowers Price Target to $14

<p>Evercore ISI Group  analyst James West   downgrades Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) from Outperform to In-Line and lowers the price target from $64 to $41.</p>


Evercore ISI Group Downgrades Noble Corp to In-Line, Lowers Price Target to $41

<p>OS Therapies reiterates clinical and regulatory path in recurrent, fully respected osteosarcoma with lung metastases, an indication with no currently approved treatments.</p>
<p><br />&nbsp;</p>


OSTX

OS Therapies Says Phase 2b Clinical Trial Of OST-HER2 Achieves Primary Endpoint With Statistical Significance In Prevention Of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Interview

BlackRock CEO Larry Fink Says Don't Believe You'll See BlackRock In The Market Buying Whole Companies

<p>Evercore ISI Group  analyst James West   downgrades Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) from Outperform to In-Line and lowers the price target from $48 to $39.</p>


Evercore ISI Group Downgrades Helmerich & Payne to In-Line, Lowers Price Target to $39

WIIM

Bank of New York Mellon shares are trading higher following better-than-expected Q4 financial results.

SPRC

SciSparc Says It Is Granted 180-Day Extension Until July 14, 2025, By Nasdaq To Regain Compliance With Minimum Bid Requirement

<p><strong>GS: 3% &#x7C; </strong><a href="https://www.benzinga.com//node/42999133">Goldman Sachs Q4 Investment Banking Fees Rose 24% YoY, Global Banking &amp; Markets Revenue Rose 33%, Provision For Credit Losses Fell 39%</a></p>
<p>&nbsp;</p>
<p><strong>VCEL: -12% &#x7C; </strong><a href="https://www.benzinga.com//node/42997435">Vericel shares are trading lower after the company issued preliminary FY24 and Q4 net revenue below estimates.</a></p>
<p>&nbsp;</p>
<p><strong>COMP: 11% &#x7C; </strong><a href="https://www.benzinga.com//node/42998131">Compass shares are trading higher after the company raised its Q4 and FY24 guidance.</a></p>


Movers

Trading Ideas

COMP

VCEL

Market-Moving News for January 15th

AVXL

Anavex Life Sciences Reveals Peer-reviewed Publication Of Oral Blarcamesine Phase IIb/III Data In Journal Of Prevention Of Alzheimer's Disease

<p>Seaport Global  analyst Kenneth Zener   upgrades KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) from Sell to Neutral.</p>


Upgrades

Seaport Global Upgrades KB Home to Neutral

<p>Prairie expects Average Daily Production: 7,000 – 8,000 barrels of oil equivalent per day (BOEPD), representing a ~300% increase year-over-year.</p>
<p>Prairie plans to actively pursue additional strategic acquisition opportunities, the completion of which will result in an update to guidance to reflect the enhanced scale and value of the Company.</p>


Guidance

PROP

Prairie Operating Expects 2025 Net Income  Of $69M - $102M, Adjusted EBITDA Of $100M - $140M,

Earnings

Goldman Sachs Total Loans Increased 7% During The Year

QBTS

D-wave Quantum Inks Pact With Carahsoft Partner To Expand Distribution Of Quantum Computing Solutions To The Public Sector

<p>Rosenblatt  analyst Blair Abernethy   maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and maintains $18 price target.</p>


SVCO

Rosenblatt Maintains Buy on Silvaco Group, Maintains $18 Price Target

ZLAB

Zai Lab Highlights Topline Results For TIVDAK In China Subpopulation Of Global Phase 3 innovaTV 301 Trial In Patients With Recurrent or Metastatic Cervical Cancer

Contracts

STRM

Streamline Health Signs New Contract For Use Of eValuator With Deaconess Health System

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Companies have clearly defined goals: to grow their customer base, brand power, and global influence, compete with giants like <strong>Nvidia</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/"><strong>NVDA</strong></a>), <strong>Meta</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/meta-stock-quote/"><strong>META</strong></a>), <strong>Apple</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/"><strong>AAPL</strong></a>), <strong>Microsoft</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/"><strong>MSFT</strong></a>) and <strong>Alphabet</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/goog-stock-quote/"><strong>GOOG</strong></a>, NASDAQ:<a href="https://investorplace.com/stock-quotes/googl-stock-quote/"><strong>GOOGL</strong></a>), and join the shortlist of trillion-dollar stocks.&nbsp;</p>



<p>While this sounds great, reaching a trillion-dollar market cap is a tough mountain to climb. Companies on their way to this peak should offer superior products that their clients love and adapt to the market&rsquo;s continuously evolving needs.&nbsp;</p>



<p>Like anyone wanting to enjoy a comfortable retirement, I, too, would like to own companies that give me that potential. So, in this article, I&rsquo;ll shortlist three buy-rated companies that I think have the potential to reach the trillion-dollar milestone. </p>



<p>To come up with the list, I screened for the following criteria:</p>



<ol><li>Companies nearing $1 trillion market cap/valuations</li>



<li>Buy-rated stocks</li>



<li>Double-digit quarterly or yearly revenue growth year over year (according to the latest reporting period)</li>
</ol><p>I then sorted the results from farthest to closest based on their proximity to a $1 trillion valuation.</p>



<h2>Broadcom (AVGO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/AVGO1600-300x169.jpg" alt="broadcom (AVGO) logo outside office building"><div>Source: Sasima / Shutterstock.com</div></div><p>As a leader in infrastructure software and semiconductor solutions, <strong>Broadcom</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/"><strong>AVGO</strong></a>) has a rich history and a reputation as the global leader it is today. With roots from its predecessor, Ma Bell,<strong> </strong>Broadcom has made its mark as one of the top &ldquo;go to&rdquo; companies for cybersecurity, distributed software, mainframe, data management and networking solutions.&nbsp;</p>



<p>Broadcom has further cemented its foothold in the tech sector with its recent acquisition of <a href="https://investors.broadcom.com/news-releases/news-release-details/broadcom-completes-acquisition-vmware">VMWare</a>, which helps it virtualize desktop operations systems, modernize its customer&rsquo;s private and hybrid cloud environments, and reach its goal of becoming the world&rsquo;s number one infrastructure technology firm.&nbsp;Speaking of modernization, Broadcom also has strong connections to AI with its networking products and AI accelerators for AI data centers that solidify its trajectory for growth.</p>



<p>With a market cap north of <a href="https://www.nasdaq.com/market-activity/stocks/avgo">$560 billion</a>, I won&rsquo;t blame you for saying it&rsquo;s a tad early to think it will reach the trillion-dollar mark anytime soon.&nbsp;</p>



<p>However, Broadcom has a strong portfolio of services that can help it cross the finish line. </p>



<p>Its finances aren&rsquo;t bad either, with Q1 2024 revenue <a href="https://investors.broadcom.com/news-releases/news-release-details/broadcom-inc-announces-first-quarter-fiscal-year-2024-financial">growing 34%</a>.</p>



<p>According to AVGO stock&rsquo;s <a href="https://www.nasdaq.com/market-activity/stocks/avgo/analyst-research">strong buy</a> recommendation, analysts also appear optimistic about the company&rsquo;s prospects as one of the next trillion-dollar stocks.&nbsp;</p>



<h2>Eli Lilly (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/eli-lilly-lly-stock-sign-1600-300x169.jpg" alt="Eli Lilly (LLY) sign on corporate building with blue sky in background"><div>Source: shutterstock.com/Michael Vi</div></div><p><strong>Eli Lilly </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/"><strong>LLY</strong></a>) is one of today&rsquo;s largest pharmaceutical companies. Its specializes in oncology, neuroscience, immunology and diabetes medications. Eli Lilly&rsquo;s strong list of products &mdash; Humulin, Cymbalta, Adcirca, Yentreve, and the widely popular Mounjaro and Zepbound &mdash; propelled it to greater heights.&nbsp;</p>



<p>With its market cap currently around&nbsp;<a href="https://www.nasdaq.com/market-activity/stocks/lly">$712 billion</a>, Eli Lilly is close to reaching the trillion-dollar milestone thanks to its growth products, promising pipeline, and phase 2 trials of tirzepatide in treating <a href="https://www.cedars-sinai.org/health-library/diseases-and-conditions/n/non-alcoholic-steatohepatitis-nash.html#:~:text=Non%2Dalcoholic%20steatohepatitis%20(NASH)%20is%20an%20advanced%20form%20of,to%20scarring%20of%20the%20liver.">NASH</a>.&nbsp;</p>



<p>The company&rsquo;s fiscal year 2023 financials also boasted a <a href="https://investor.lilly.com/static-files/fd0ef78b-4c48-4a15-b65b-8bf9b6ed26d2">20% year-over-year revenue growth</a>, driven by strong customer reception of its new products. The company also has a promising outlook with GAAP EPS, which is expected to reach $11.80 to $12.30, and revenue of between $40.4 billion and $41.6 billion.</p>



<p>Combine this with the <a href="https://www.nasdaq.com/market-activity/stocks/lly/analyst-research">strong buy</a> recommendation from Wall Street experts, and we may have a recipe for another trillion-dollar success.&nbsp;</p>



<h2>Berkshire Hathaway (BRK-A)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/12/brk-2-300x169.jpg" alt="The logo for Berkshire Hathaway displayed on a smartphone screen."><div>Source: IgorGolovniov / Shutterstock.com</div></div><p>While almost everyone knows its billionaire owner, Warren Buffet, <strong>Berkshire Hathaway</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/brk-a-stock-quote/"><strong>BRK-A</strong></a>) may not be as popular with non-investors. Its operations are structured as a holding company for its subsidiaries in various sectors.&nbsp;</p>



<p>Berkshire Hathaway&rsquo;s main strategy focuses on holding stakes in leading companies and buying undervalued businesses that can be derived from its proven and effective value investing philosophy. A recent example is its acquisition of the remaining <a href="https://www.berkshirehathaway.com/news/jan1624.pdf">20% interest</a> in Pilot Travel Centers LLC from <strong>Pilot Corporation</strong> (OTCMKTS:<strong><a href="https://finance.yahoo.com/quote/POGHF/">POGHF</a></strong>), which has complete ownership.</p>



<p>Of the three on our list, Berkshire Hathaway is the closest to reaching the trillion-dollar milestone, with its market cap around <a href="https://www.nasdaq.com/market-activity/stocks/brk-a">$899 billion</a>.&nbsp;</p>



<p>The company&rsquo;s upward trajectory is mostly due to its growth. FY 2023 saw an impressive <a href="https://www.berkshirehathaway.com/2023ar/2023ar.pdf">21% growth in operating earnings</a>. Net earnings reached $96 billion &mdash; a great recovery from last year&rsquo;s $23 billion loss.&nbsp;</p>



<p>No wonder analysts like those at UBS main Berkshire Hathaway&rsquo;s <a href="https://finance.yahoo.com/quote/BRK-A/analysis">buy rating</a>. Its strong management and investment philosophy rooted in Warren Buffet&rsquo;s value investing principles, which have proven effective for the company, makes it one of the next potential trillion-dollar stocks to make history.</p>



<p><em>On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines</em></a>.</p>
<div><p>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/3-stocks-gunning-for-trillion-dollar-status-the-players-to-own-now/">3 Stocks Gunning for Trillion-Dollar Status: The Players to Own Now</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Comments

Pilot

Pilot (POGHF) Forecast

Pilot (OTC:POGHF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga